Carnosine vs GHRP-6

Dipeptide that buffers lactic acid in muscle during high-intensity exercise; chelates metal ions; prevents and reverses protein glycation; scavenges aldehyde oxidative byproducts

Carnosine is a naturally occurring dipeptide (β-alanyl-L-histidine) synthesized in skeletal muscle and other excitable tissues from β-alanine and histidine, where it functions as an intracellular pH buffer, antioxidant, and antiglycation agent that supports cellular homeostasis under metabolic stress. Its principal role in exercise physiology centers on buffering the proton accumulation associated with high-intensity anaerobic work, attenuating acidosis-driven impairment of contractile function and extending time to fatigue during supra-threshold effort. Human randomized controlled trials using β-alanine supplementation — which elevates muscle carnosine content by increasing substrate availability — have demonstrated attenuation of fatigue during repeated high-intensity exercise bouts in trained athletes, providing the primary human evidence base for carnosine's performance effects. Carnosine is available as an oral dietary supplement in many jurisdictions; the evidence base for muscle carnosine loading via oral β-alanine supplementation is established in human RCTs, while direct exogenous carnosine administration by injection remains investigational with no regulatory approval or established clinical evidence base.

Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) in pituitary somatotrophs and the hypothalamus, stimulating GH release through a mechanism that is synergistic with but distinct from endogenous growth hormone-releasing hormone (GHRH). Like other GHRP-class peptides, it engages hypothalamic arcuate nucleus circuits to potentiate GHRH-driven GH pulses and partially suppress somatostatin inhibitory tone; it was among the first GHRP-class compounds characterized pharmacologically and has been used extensively as a research tool for probing the GH secretory axis. Clinical studies have demonstrated dose-dependent GH release following GHRP-6 administration in human subjects, and the GHRP pharmacological class has been characterized across multiple studies documenting pituitary and hypothalamic mechanisms of action. GHRP-6 is not FDA-approved for any indication; it has been studied as a pharmacological tool and provocative GH stimulation agent but has not been evaluated for safety or efficacy in performance enhancement or muscle building outside research protocols. GHRP-6 dosage in research contexts: studies have used subcutaneous and intravenous doses typically in the range of 100–300 mcg per injection. In research protocols, GHRP-6 is often administered 2–3 times daily — before meals, before training, or before sleep — to leverage the body's natural GH pulse windows. GHRP-6 produces a pronounced appetite stimulation effect (a direct ghrelin-mimetic consequence) that is stronger than what is observed with more selective GHRPs such as ipamorelin; this characteristic is relevant to research contexts studying GH secretion alongside energy intake regulation. GHRP-6 vs GHRP-2: both are non-selective GHRPs producing GH alongside cortisol and prolactin co-stimulation, but GHRP-6 is noted for more pronounced ghrelin-like appetite stimulation, while GHRP-2 produces greater GH output per unit dose in some comparative studies. Neither offers the selectivity profile of ipamorelin, which emerged from subsequent GHRP research specifically to reduce off-target hormonal effects. GHRP-6 is administered by subcutaneous injection following reconstitution with bacteriostatic water. Providers offering GHRP-class secretagogues are listed in the PeptideBase directory.